Divalproex Sodium: Package Insert and Label Information (Page 7 of 7)

14.2 Epilepsy

The efficacy of valproate in reducing the incidence of complex partial seizures (CPS) that occur in isolation or in association with other seizure types was established in two controlled trials.

In one, multi-clinic, placebo controlled study employing an add-on design (adjunctive therapy), 144 patients who continued to suffer eight or more CPS per 8 weeks during an 8 week period of monotherapy with doses of either carbamazepine or phenytoin sufficient to assure plasma concentrations within the “therapeutic range” were randomized to receive, in addition to their original antiepilepsy drug (AED), either divalproex sodium delayed-release tablets or placebo. Randomized patients were to be followed for a total of 16 weeks. The following table presents the findings.

Table 8. Adjunctive Therapy Study Median Incidence of CPS per 8 Weeks
*
Reduction from baseline statistically significantly greater for valproate than placebo at p ≤ 0.05 level.
Add on Treatment Number of Patients Baseline Incidence Experimental Incidence
Divalproex sodium delayed-release tablets7516.08.9*
Placebo6914.511.5

Figure 2 presents the proportion of patients (X axis) whose percentage reduction from baseline in complex partial seizure rates was at least as great as that indicated on the Y axis in the adjunctive therapy study. A positive percent reduction indicates an improvement (i.e., a decrease in seizure frequency), while a negative percent reduction indicates worsening. Thus, in a display of this type, the curve for an effective treatment is shifted to the left of the curve for placebo. This figure shows that the proportion of patients achieving any particular level of improvement was consistently higher for valproate than for placebo. For example, 45% of patients treated with valproate had a ≥ 50% reduction in complex partial seizure rate compared to 23% of patients treated with placebo.

Figure 2

Fig 2
(click image for full-size original)

The second study assessed the capacity of valproate to reduce the incidence of CPS when administered as the sole AED. The study compared the incidence of CPS among patients randomized to either a high or low dose treatment arm. Patients qualified for entry into the randomized comparison phase of this study only if 1) they continued to experience 2 or more CPS per 4 weeks during an 8 to 12 week long period of monotherapy with adequate doses of an AED (i.e., phenytoin, carbamazepine, phenobarbital, or primidone) and 2) they made a successful transition over a two week interval to valproate. Patients entering the randomized phase were then brought to their assigned target dose, gradually tapered off their concomitant AED and followed for an interval as long as 22 weeks. Less than 50% of the patients randomized, however, completed the study. In patients converted to divalproex sodium delayed-release tablets monotherapy, the mean total valproate concentrations during monotherapy were 71 and 123 mcg/mL in the low dose and high dose groups, respectively.

The following table presents the findings for all patients randomized who had at least one post-randomization assessment.

Table 9. Monotherapy Study Median Incidence of CPS per 8 Weeks
*
Reduction from baseline statistically significantly greater for high dose than low dose at p ≤ 0.05 level.
Treatment Number of Patients Baseline Incidence Randomized Phase Incidence
High dose Divalproex sodium delayed-release tablets13113.210.7*
Low dose Divalproex sodium delayed-release tablets13414.213.8

Figure 3 presents the proportion of patients (X axis) whose percentage reduction from baseline in complex partial seizure rates was at least as great as that indicated on the Y axis in the monotherapy study. A positive percent reduction indicates an improvement (i.e., a decrease in seizure frequency), while a negative percent reduction indicates worsening. Thus, in a display of this type, the curve for a more effective treatment is shifted to the left of the curve for a less effective treatment. This figure shows that the proportion of patients achieving any particular level of reduction was consistently higher for high dose valproate than for low dose valproate. For example, when switching from carbamazepine, phenytoin, phenobarbital or primidone monotherapy to high dose valproate monotherapy, 63% of patients experienced no change or a reduction in complex partial seizure rates compared to 54% of patients receiving low dose valproate.

Figure 3

Fig 3
(click image for full-size original)

Information on pediatric studies is presented in section 8.

14.3 Migraine

The results of two multicenter, randomized, double-blind, placebo-controlled clinical trials established the effectiveness of divalproex sodium delayed-release tablets in the prophylactic treatment of migraine headache.

Both studies employed essentially identical designs and recruited patients with a history of migraine with or without aura (of at least 6 months in duration) who were experiencing at least 2 migraine headaches a month during the 3 months prior to enrollment. Patients with cluster headaches were excluded. Women of childbearing potential were excluded entirely from one study, but were permitted in the other if they were deemed to be practicing an effective method of contraception.

In each study following a 4-week single-blind placebo baseline period, patients were randomized, under double blind conditions, to divalproex sodium delayed-release tablets or placebo for a 12-week treatment phase, comprised of a 4-week dose titration period followed by an 8-week maintenance period. Treatment outcome was assessed on the basis of 4-week migraine headache rates during the treatment phase.

In the first study, a total of 107 patients (24 M, 83 F), ranging in age from 26 to 73 were randomized 2:1, divalproex sodium delayed-release tablets to placebo. Ninety patients completed the 8-week maintenance period. Drug dose titration, using 250 mg tablets, was individualized at the investigator’s discretion. Adjustments were guided by actual/sham trough total serum valproate levels in order to maintain the study blind. In patients on divalproex sodium delayed-release tablet doses ranged from 500 to 2,500 mg a day. Doses over 500 mg were given in three divided doses (TID). The mean dose during the treatment phase was 1,087 mg/day resulting in a mean trough total valproate level of 72.5 mcg/mL, with a range of 31 to 133 mcg/mL.

The mean 4-week migraine headache rate during the treatment phase was 5.7 in the placebo group compared to 3.5 in the divalproex sodium delayed-release tablets group (see Figure 4). These rates were significantly different.

In the second study, a total of 176 patients (19 males and 157 females), ranging in age from 17 to 76 years, were randomized equally to one of three divalproex sodium delayed-release tablets dose groups (500, 1,000, or 1,500 mg/day) or placebo. The treatments were given in two divided doses (BID). One hundred thirty-seven patients completed the 8-week maintenance period. Efficacy was to be determined by a comparison of the 4-week migraine headache rate in the combined 1,000/1,500 mg/day group and placebo group.

The initial dose was 250 mg daily. The regimen was advanced by 250 mg every 4 days (8 days for 500 mg/day group), until the randomized dose was achieved. The mean trough total valproate levels during the treatment phase were 39.6, 62.5, and 72.5 mcg/mL in the divalproex sodium delayed-release tablets 500, 1,000, and 1,500 mg/day groups, respectively.

The mean 4-week migraine headache rates during the treatment phase, adjusted for differences in baseline rates, were 4.5 in the placebo group, compared to 3.3, 3.0, and 3.3 in the divalproex sodium delayed-release tablets 500, 1,000, and 1,500 mg/day groups, respectively, based on intent-to-treat results (see Figure 4). Migraine headache rates in the combined divalproex sodium delayed-release tablets 1,000/1,500 mg group were significantly lower than in the placebo group.

Figure 4 Mean 4-week Migraine Rates

Figure 4
(click image for full-size original)
  1. Mean dose of divalproex sodium delayed-release tablets were 1,087 mg/day.
  2. Dose of divalproex sodium delayed-release tablets were 500 or 1,000 mg/day.
Figure 2Fig 2Fig 3Figure 4

15 REFERENCES

1. Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology 2013; 12 (3):244-252.

16 HOW SUPPLIED/STORAGE AND HANDLING

Divalproex sodium delayed-release tablets USP are supplied as:

125 mg (as valproic acid) pink colored, oval shaped, biconvex, enteric coated tablets, imprinted with “L005” (in black ink) on one side and plain on the other side.

Bottles of 100 NDC 68180-265-01

Bottles of 500 NDC 68180-265-02

Box containing 10 x 10’s unit dose tablets NDC 68180-265-13

250 mg (as valproic acid) pink colored, oval shaped, biconvex, enteric coated tablets, imprinted with “L006” (in black ink) on one side and plain on the other side.

Bottles of 100 NDC 68180-266-01

Bottles of 500 NDC 68180-266-02

Bottles of 1000 NDC 68180-266-03

Box containing 10 x 10’s unit dose tablets NDC 68180-266-13

500 mg (as valproic acid) pink colored, oval shaped, biconvex, enteric coated tablets, imprinted with “L007” (in black ink) on one side and plain on the other side.

Bottles of 100 NDC 68180-267-01

Bottles of 500 NDC 68180-267-02

Bottles of 1000 NDC 68180-267-03

Box containing 10 x 10’s unit dose tablets NDC 68180-267-13

Recommended storage

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Hepatotoxicity

Warn patients and guardians that nausea, vomiting, abdominal pain, anorexia, diarrhea, asthenia, and/or jaundice can be symptoms of hepatotoxicity and, therefore, require further medical evaluation promptly [see Warnings and Precautions (5.1)].

Pancreatitis

Warn patients and guardians that abdominal pain, nausea, vomiting, and/or anorexia can be symptoms of pancreatitis and, therefore, require further medical evaluation promptly [see Warnings and Precautions (5.5)].

Birth Defects and Decreased IQ

Inform pregnant women and women of childbearing potential (including girls beginning the onset of puberty) that use of valproate during pregnancy increases the risk of birth defects, decreased IQ, and neurodevelopmental disorders in children who were exposed in utero. Advise women to use effective contraception while taking valproate. When appropriate, counsel these patients about alternative therapeutic options. This is particularly important when valproate use is considered for a condition not usually associated with permanent injury or death such as prophylaxis of migraine headache [see Contraindications (4)]. Advise patients to read the Medication Guide, which appears as the last section of the labeling [see Warnings and Precautions (5.2, 5.3, 5.4) and Use in Specific Populations (8.1)].

Pregnancy Registry

Advise women of childbearing potential to discuss pregnancy planning with their doctor and to contact their doctor immediately if they think they are pregnant.

Encourage women who are taking divalproex sodium delayed-release tablets to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 or visit the website, http://www.aedpregnancyregistry.org/ [see Use in Specific Populations (8.1)].

Suicidal Thinking and Behavior

Counsel patients, their caregivers, and families that AEDs, including divalproex sodium delayed-release tablets, may increase the risk of suicidal thoughts and behavior and to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Instruct patients, caregivers, and families to report behaviors of concern immediately to the healthcare providers [see Warnings and Precautions (5.7)].

Hyperammonemia

Inform patients of the signs and symptoms associated with hyperammonemic encephalopathy and to notify the prescriber if any of these symptoms occur [see Warnings and Precautions (5.9, 5.10)].

CNS Depression

Since valproate products may produce CNS depression, especially when combined with another CNS depressant (e.g., alcohol), advise patients not to engage in hazardous activities, such as driving an automobile or operating dangerous machinery, until it is known that they do not become drowsy from the drug.

Multiorgan Hypersensitivity Reactions

Instruct patients that a fever associated with other organ system involvement (rash, lymphadenopathy, etc.) may be drug-related and should be reported to the physician immediately [see Warnings and Precautions (5.12)].

Medication Residue in the Stool

Instruct patients to notify their healthcare provider if they notice a medication residue in the stool

[see Warnings and Precautions (5.18)].

Manufactured for:

Lupin Pharmaceuticals, Inc.

Baltimore, Maryland 21202

United States.

Manufactured by:

Lupin Limited

Goa 403 722

INDIA.

Revised: May 2021 ID#: 267814

MEDICATION GUIDE

Divalproex Sodium (dye val’ proe ex soe’ dee um)

Delayed-Release Tablets

Rx only

Read this Medication Guide before you start taking divalproex sodium delayed-release tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.

What is the most important information I should know about divalproex sodium delayed-release tablets ?

Do not stop taking divalproex sodium delayed-release tablets without first talking to your healthcare provider.

Stopping divalproex sodium delayed-release tablets suddenly can cause serious problems.

Divalproex sodium delayed-release tablets can cause serious side effects, including:

1. Serious liver damage that can cause death, especially in children younger than 2 years old.

The risk of getting this serious liver damage is more likely to happen within the first 6 months of treatment.

Call your healthcare provider right away if you get any of the following symptoms:

  • nausea or vomiting that does not go away
  • loss of appetite
  • pain on the right side of your stomach (abdomen)
  • dark urine
  • swelling of your face
  • yellowing of your skin or the whites of your eyes

In some cases, liver damage may continue despite stopping the drug.

2. Divalproex sodium delayed-release tablets may harm your unborn baby.

If you take divalproex sodium delayed-release tablets during pregnancy for any medical condition, your baby is at risk for serious birth defects that affect the brain and spinal cord and are called spina bifida or neural tube defects. These defects occur in 1 to 2 out of every 100 babies born to mothers who use this medicine during pregnancy. These defects can begin in the first month, even before you know you are pregnant. Other birth defects that affect the structures of the heart, head, arms, legs, and the opening where the urine comes out (urethra) on the bottom of the penis can also happen. Decreased hearing or hearing loss can also happen.

Birth defects may occur even in children born to women who are not taking any medicines and do not have other risk factors.

Taking folic acid supplements before getting pregnant and during early pregnancy can lower the chance of having a baby with a neural tube defect.

If you take divalproex sodium delayed-release tablets during pregnancy for any medical condition, your child is at risk for having lower IQ and may be at risk for developing autism or attention deficit/hyperactivity disorder.

There may be other medicines to treat your condition that have a lower chance of causing birth defects, decreased IQ, or other disorders in your child.

  • Women who are pregnant must not take divalproex sodium delayed-release tablets to prevent migraine headaches.

All women of childbearing age (including girls from the start of puberty) should talk to their healthcare provider about using other possible treatments instead of divalproex sodium delayed-release tablets. If the decision is made to use divalproex sodium delayed-release tablets, you should use effective birth control (contraception).

Tell your healthcare provider right away if you become pregnant while taking divalproex sodium delayed-release tablets. You and your healthcare provider should decide if you will continue to take divalproex sodium delayed-release tablets while you are pregnant.

Pregnancy Registry: If you become pregnant while taking divalproex sodium delayed-release tablets, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling toll-free 1-888-233-2334 or by visiting the website, http://www.aedpregnancyregistry.org/. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy.

3. Inflammation of your pancreas that can cause death.

Call your healthcare provider right away if you have any of these symptoms:

  • severe stomach pain that you may also feel in your back
  • nausea or vomiting that does not go away

4. Like other antiepileptic drugs, divalproex sodium delayed-release tablets may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.

Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:

  • thoughts about suicide or dying
  • attempts to commit suicide
  • new or worse depression
  • new or worse anxiety
  • feeling agitated or restless
  • panic attacks
  • trouble sleeping (insomnia)
  • new or worse irritability
  • acting aggressive, being angry, or violent
  • acting on dangerous impulses
  • an extreme increase in activity and talking (mania)
  • other unusual changes in behavior or mood

How can I watch for early symptoms of suicidal thoughts and actions?

  • Pay attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings.
  • Keep all follow-up visits with your healthcare provider as scheduled.

Call your healthcare provider between visits as needed, especially if you are worried about symptoms.

Do not stop divalproex sodium delayed-release tablets without first talking to a healthcare provider.

Stopping divalproex sodium delayed-release tablets suddenly can cause serious problems. Stopping a seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus).

Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.

What are divalproex sodium delayed-release tablets?

Divalproex sodium delayed-release tablets come in different dosage forms with different usages.

Divalproex sodium delayed-release tablets are prescription medicines used:

• to treat manic episodes associated with bipolar disorder

• alone or with other medicines to treat:

• complex partial seizures in adults and children 10 years of age and older

• simple and complex absence seizures, with or without other seizure types

• to prevent migraine headaches

Who should not take divalproex sodium delayed-release tablets?

Do not take divalproex sodium delayed-release tablets if you:

  • have liver problems
  • have or think you have a genetic liver problem caused by a mitochondrial disorder (e.g.
  • Alpers-Huttenlocher syndrome)
  • are allergic to divalproex sodium, valproic acid, sodium valproate, or any of the ingredients in divalproex sodium delayed-release tablets. See the end of this leaflet for a complete list of ingredients in divalproex sodium delayed-release tablets.
  • have a genetic problem called urea cycle disorder
  • are taking it to prevent migraine headaches and are either pregnant or may become pregnant because you are not using effective birth control (contraception)

What should I tell my healthcare provider before taking divalproex sodium delayed-release tablets?

Before you take divalproex sodium delayed-release tablets, tell your healthcare provider if you:

  • have a genetic liver problem caused by a mitochondrial disorder (e.g. Alpers-Huttenlocher syndrome)
  • drink alcohol
  • are pregnant or breastfeeding. Divalproex sodium can pass into breast milk. Talk to your healthcare provider about the best way to feed your baby if you take divalproex sodium delayed-release tablets.
  • have or have had depression, mood problems, or suicidal thoughts or behavior
  • have any other medical conditions

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, herbal supplements and medicines that you take for a short period of time.

Taking divalproex sodium delayed-release tablets with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider.

Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist each time you get a new medicine.

How should I take divalproex sodium delayed-release tablets?

  • Take divalproex sodium delayed-release tablets exactly as your healthcare provider tells you. Your healthcare provider will tell you how much divalproex sodium delayed-release tablets to take and when to take it.
  • Your healthcare provider may change your dose.
  • Do not change your dose of divalproex sodium delayed-release tablets without talking to your healthcare provider.
  • Do not stop taking divalproex sodium delayed-release tablets without first talking to your healthcare provider. Stopping divalproex sodium delayed-release tablets suddenly can cause serious problems.
  • Swallow divalproex sodium delayed-release tablets whole. Do not crush or chew divalproex sodium delayed-release tablets. Tell your healthcare provider if you cannot swallow divalproex sodium delayed-release tablets whole. You may need a different medicine.
  • If you take too much divalproex sodium delayed-release tablets, call your healthcare provider or local Poison Control Center right away.

What should I avoid while taking divalproex sodium delayed-release tablets?

  • Divalproex sodium delayed-release tablets can cause drowsiness and dizziness. Do not drink alcohol or take other medicines that make you sleepy or dizzy while taking divalproex sodium delayed-release tablets, until you talk with your doctor. Taking divalproex sodium delayed-release tablets with alcohol or drugs that cause sleepiness or dizziness may make your sleepiness or dizziness worse.
  • Do not drive a car or operate dangerous machinery until you know how divalproex sodium delayed-release tablets affect you. Divalproex sodium delayed-release tablets can slow your thinking and motor skills.

What are the possible side effects of divalproex sodium delayed-release tablets?

  • See “What is the most important information I should know about divalproex sodium delayed-release tablets?”

Divalproex sodium delayed-release tablets can cause serious side effects including:

  • Bleeding problems: red or purple spots on your skin, bruising, pain and swelling into your joints due to bleeding or bleeding from your mouth or nose.
  • High ammonia levels in your blood: feeling tired, vomiting, changes in mental status.
  • Low body temperature (hypothermia): drop in your body temperature to less than 95 F, feeling tired, confusion, coma.
  • Allergic (hypersensitivity) reactions: fever, skin rash, hives, sores in your mouth, blistering and peeling of your skin, swelling of your lymph nodes, swelling of your face, eyes, lips, tongue, or throat, trouble swallowing or breathing.
  • Drowsiness or sleepiness in the elderly. This extreme drowsiness may cause you to eat or drink less than you normally would. Tell your doctor if you are not able to eat or drink as you normally do. Your doctor may start you at a lower dose of divalproex sodium delayed-release tablets.

Call your healthcare provider right away, if you have any of the symptoms listed above.

The common side effects of divalproex sodium delayed-release tablets include:

  • nausea
  • headache
  • sleepiness
  • vomiting
  • weakness
  • tremor
  • dizziness
  • stomach pain
  • blurry vision
  • double vision
  • diarrhea
  • increased appetite
  • weight gain
  • hair loss
  • loss of appetite
  • problems with walking or coordination

These are not all of the possible side effects of divalproex sodium delayed-release tablets. For more information, ask your healthcare provider or pharmacist.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store divalproex sodium delayed-release tablets ?

  • Store divalproex sodium delayed-release tablets between 59° to 86°F (15° to 30°C).

Keep divalproex sodium delayed-release tablets and all medicines out of the reach of children.

General information about the safe and effective use of divalproex sodium delayed-release tablets

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use divalproex sodium delayed-release tablets for a condition for which it was not prescribed. Do not give divalproex sodium delayed-release tablets to other people, even if they have the same symptoms that you have. It may harm them.

This Medication Guide summarizes the most important information about divalproex sodium delayed-release tablets. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about divalproex sodium delayed-release tablets that is written for health professionals.

For more information, go to www.lupinpharmaceuticals.com or call 1-800-399-2561.

What are the ingredients in divalproex sodium delayed-release tablets?

Active ingredient: divalproex sodium

Inactive ingredients:

Colloidal silicon dioxide, D&C Red No. 30, FD&C Blue No. 2, hydroxylpropyl cellulose, hypromellose, hypromellose phthalate, iron oxide black, iron oxide yellow, low substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, pregelatinised starch, propylene glycol, shellac, talc, titanium dioxide and triethyl citrate.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

® The brands listed are trademarks of their respective owners and are not trademarks of Lupin Pharmaceuticals, Inc. The makers of these brands are not affiliated with and do not endorse Lupin Pharmaceuticals, Inc. or its products.

Manufactured for:

Lupin Pharmaceuticals, Inc.

Baltimore, Maryland 21202

United States.

Manufactured by:

Lupin Limited

Goa 403 722

INDIA.

Revised: July 2020 ID#: 265519

Divalproex Sodium Delayed-release Tablets USP, 125 mg

Rx Only

NDC 68180-265-01

100 Tablets

Fig 6
(click image for full-size original)

Divalproex Sodium Delayed-release Tablets USP, 250 mg

Rx Only

NDC 68180-266-01

100 Tablets

Fig 7
(click image for full-size original)

Divalproex Sodium Delayed-release Tablets USP, 500 mg

Rx Only

NDC 68180-267-01

100 Tablets

Figure 8
(click image for full-size original)
DIVALPROEX SODIUM divalproex sodium tablet, delayed release
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68180-265
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
DIVALPROEX SODIUM (VALPROIC ACID) VALPROIC ACID 125 mg
Inactive Ingredients
Ingredient Name Strength
D&C RED NO. 30
FD&C BLUE NO. 2
FERRIC OXIDE YELLOW
HYPROMELLOSES
SILICON DIOXIDE
TRIETHYL CITRATE
CELLULOSE, MICROCRYSTALLINE
HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)
HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
SHELLAC
TALC
HYDROXYPROPYL CELLULOSE (1600000 WAMW)
MAGNESIUM STEARATE
PROPYLENE GLYCOL
TITANIUM DIOXIDE
FERROSOFERRIC OXIDE
STARCH, CORN
Product Characteristics
Color PINK Score no score
Shape OVAL (Oval Shaped Biconvex) Size 11mm
Flavor Imprint Code L005
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:68180-265-11 10 TABLET, DELAYED RELEASE in 1 BLISTER PACK None
2 NDC:68180-265-02 500 TABLET, DELAYED RELEASE in 1 BOTTLE None
3 NDC:68180-265-01 100 TABLET, DELAYED RELEASE in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA078790 07/29/2008
DIVALPROEX SODIUM divalproex sodium tablet, delayed release
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68180-266
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
DIVALPROEX SODIUM (VALPROIC ACID) VALPROIC ACID 250 mg
Inactive Ingredients
Ingredient Name Strength
D&C RED NO. 30
FD&C BLUE NO. 2
FERRIC OXIDE YELLOW
HYPROMELLOSES
SILICON DIOXIDE
TRIETHYL CITRATE
CELLULOSE, MICROCRYSTALLINE
HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)
HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
SHELLAC
TALC
HYDROXYPROPYL CELLULOSE (1600000 WAMW)
MAGNESIUM STEARATE
PROPYLENE GLYCOL
TITANIUM DIOXIDE
FERROSOFERRIC OXIDE
STARCH, CORN
Product Characteristics
Color PINK Score no score
Shape OVAL (Oval Biconvex) Size 14mm
Flavor Imprint Code L006
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:68180-266-01 100 TABLET, DELAYED RELEASE in 1 BOTTLE None
2 NDC:68180-266-03 1000 TABLET, DELAYED RELEASE in 1 BOTTLE None
3 NDC:68180-266-02 500 TABLET, DELAYED RELEASE in 1 BOTTLE None
4 NDC:68180-266-11 10 TABLET, DELAYED RELEASE in 1 BLISTER PACK None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA078790 07/29/2008
DIVALPROEX SODIUM divalproex sodium tablet, delayed release
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68180-267
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
DIVALPROEX SODIUM (VALPROIC ACID) VALPROIC ACID 500 mg
Inactive Ingredients
Ingredient Name Strength
D&C RED NO. 30
FD&C BLUE NO. 2
FERRIC OXIDE YELLOW
HYPROMELLOSES
SILICON DIOXIDE
TRIETHYL CITRATE
CELLULOSE, MICROCRYSTALLINE
HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)
HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
SHELLAC
TALC
HYDROXYPROPYL CELLULOSE (1600000 WAMW)
MAGNESIUM STEARATE
PROPYLENE GLYCOL
TITANIUM DIOXIDE
FERROSOFERRIC OXIDE
STARCH, CORN
Product Characteristics
Color PINK Score no score
Shape OVAL (Oval shaped Biconvex) Size 19mm
Flavor Imprint Code L007
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:68180-267-01 100 TABLET, DELAYED RELEASE in 1 BOTTLE None
2 NDC:68180-267-11 10 TABLET, DELAYED RELEASE in 1 BLISTER PACK None
3 NDC:68180-267-03 1000 TABLET, DELAYED RELEASE in 1 BOTTLE None
4 NDC:68180-267-02 500 TABLET, DELAYED RELEASE in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA078790 07/29/2008
Labeler — Lupin Pharmaceuticals, Inc. (089153071)
Registrant — LUPIN LIMITED (675923163)
Establishment
Name Address ID/FEI Operations
LUPIN LIMITED 677600414 MANUFACTURE (68180-265), MANUFACTURE (68180-266), MANUFACTURE (68180-267), PACK (68180-265), PACK (68180-266), PACK (68180-267)

Revised: 05/2021 Lupin Pharmaceuticals, Inc.

DrugInserts.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the US Food and Drug Administration. Package information is not reviewed or updated separately by DrugInserts.com. Every individual package label entry contains a unique identifier which can be used to secure further details directly from the US National Institutes of Health and/or the FDA.

As the leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. Our material is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2021. All Rights Reserved.